Table 1 Clinical information and treatment of the two groups
Clinical information and treatment | NP group (n = 37) | Control group (n = 74) | P value |
|---|---|---|---|
Clinical presentation (n, %) | |||
Fever | 37, 100% | 74, 100% | – |
Cough | 37, 100% | 74, 100% | – |
Chest pain | 3, 8.1% | 0 | 0.035a |
dyspnea | 4, 10.8% | 3, 4.1% | 0.334 |
Extrapulmonary complications (n, %) | |||
Elevated liver enzyme level | 10, 27% | 28, 37.8% | 0.258 |
Electrolyte disturbance | 4, 10.8% | 6, 8.1% | 0.907 |
Hypoproteinemia | 4, 10.8% | 2, 2.7% | 0.182 |
Coronary dilatation | 0 | 1, 1.4% | 1.000a |
Pericardial effusion | 0 | 1, 1.4% | 1.000a |
Polymorphic erythema | 0 | 1, 1.4% | 1.000a |
Treatment (n, %) | |||
Administered other antibiotics | 34, 91.9% | 51, 68.9% | 0.007 |
Noninvasive ventilation | 1, 2.7% | 0 | 0.722 |
Low molecular weight heparin | 13, 35.1% | 42, 58.1% | 0.032 |
Methylprednisolone | 30, 81.1% | 65, 87.8% | 0.339 |
Intravenous immunoglobulin | 10, 27% | 8, 10.8% | 0.029 |
Fiber bronchoscope examination | 23, 62.2% | 48, 64.9% | 0.780 |
Mucous congestion, edema | 23, 100% | 48, 100% | 0.780 |
Bronchitis obliterans | 1, 4.3% | 0 | 0.324a |
Plastic bronchitis | 1, 4.3% | 0 | 0.324a |